Summary Two hundred and thirty five patients with osteosarcoma, aged less than 40 years, and treated by amputation or radiotherapy, were entered in a randomised trial of two forms of adjuvant chemotherapy. A two drug regimen, namely vincristine 2 mg m -2 (maximum 2 mg) followed by methotrexate 200 mgm-2, given every three weeks, was compared with a three drug regimen, comprising the same vincristine-methotrexate treatment, alternating every three weeks with doxorubicin 60 mgm-2. Both regimens were continued for 54 weeks. Forty-one patients were excluded, most because of inadequate histology, leaving 194 patients for analysis. One hundred and seventy of these had immediate amputation, 14 were treated by a policy of radiotherapy, with surgery delayed for 9 months, provided no distant metastases had appeared, and 10 by a policy of radiotherapy only. Patients have been followed-up for between 26 and 94 months after entry to the trial. The 2-and 5-year survival rates were 48% and 27%. No significant difference in survival was observed between the two regimens, but toxicity was less with the two drug regimen.
Although osteosarcoma is the commonest primary malignant tumour of bone, the total number of deaths registered annually in the United Kingdom is less than 150. The 5-year survival rate 15 years ago was about 20-25% (Sweetnam et al., 1971; Price, 1967; Dahlin & Coventry, 1967) . There was little difference between the survival rate of patients treated by immediate primary amputation and those treated by the 'Cade policy', that is by radiotherapy, with amputation delayed for 6 to 9 months, or abandoned if there was earlier evidence of metastases (Cade, 1955) .
Lung metastases occur early in the disease and are present in about 80% of patients by 2 years after presentation. It was thus realised that improvement in survival rate would depend on finding a method of eradicating the occult pulmonary metastases. Response of lung metastases to methotrexate used in high dosage with folinic acid rescue (Jaffe et al., 1973) and to doxorubicin (Cortes et al., 1972) was reported, followed by preliminary reports of clinical advantage to patients treated with these drugs as an adjuvant to surgery (Jaffe et al., 1974; Cortes et al., 1974 was not ethical to deny adjuvant treatment to any patient. The suggestion was therefore abandoned.
Patients and methods
The object of the trial was to compare the efficacy of two regimens of adjuvant cytotoxic drugs in the control of occult lung metastases that might be present in osteosarcoma patients treated by amputation or by irradiation. The patients were assessed regularly with regard to survival, the appearance and progress of lung metastases and performance status.
The diagnosis of osteosarcoma was confirmed by biopsy; other mandatory investigations included lung tomography, and a skeletal survey either by radiograph or isotope scan. Patients The prescribed duration of chemotherapy in each series was 54 weeks.
Two hundred patients were required to give an 80% chance of detecting a 20% difference in the 5-year survival rate between the two treatment groups. A randomisation scheme which stratified patients by age, initial treatment to the primary disease, and centre was adopted.
Patients were followed up by X-ray examination every 6 weeks to 18 months, then every 3 months to 5 years and then annually. Blood was examined every 3 weeks for the first year, and then at the same times as the X-ray examinations. given a reduced dose of vincristine and the remainder continued on the regimen. Nine patients were noted to have biochemical evidence of minor liver toxicity and seven showed evidence of renal toxicity. In all cases this was transient, requiring a delay in treatment for one of the patients with liver toxicity and 3 of those with renal toxicity. In addition to the major difference in cardiotoxicity noted above, there were more adverse reactions in patients on the three drug regimen, including myelosuppression and alopecia, and more severe nausea and vomiting.
Compliance with trial chemotherapy
Deviations from the intended chemotherapy occurred for various reasons. Seventy-nine patients (43 on the two drug and 36 on the three drug regimen) developed metastases during the treatment period and in these treatment was changed. Eighteen (9 from each group) refused to complete the course. Intercurrent illness caused delay in treatment for 11 on the two drug and 14 on the three drug regimen. Toxicity resulted in 13 patients on the two drug and 24 on the three drug regimen deviating from the three weekly cycle; this ranged from a delay in administering the drugs to a complete removal from the therapy. These figures are in line with the greater toxicity associated with the three drug regimen.
Survivalfree of lung metastases, and survival All 194 patients have been included in the survival analyses. Because of the long intake period, patients were followed for differing periods, and these ranged from 26 to 94 months after entry.
The actuarial percentage surviving free of lung metastases for 5 years was 25%. Figure 2 Actuarial probability of survival free from lung metastases against time in months since entry to trial. Two drug group ( ); three drug group (---- Sex The lung metastases-free survival curves and the total survival curves were similar for males and females. fared better than the others (9/27 surviving more than 1 year compared with 0/17).
Discussion
Entry to this trial was begun in 1975 and completed in 1981, and all 194 eligible patients are included in this analysis. The total 2-and 5-year survival rates were 48% and 27%. These are lower than the 2-year relapse free survival rates of 60-90%, falling to 40-50% by 5 years, quoted from several adjuvant series in North America (Eilber et al., 1978; Jaffe et al., 1978; Marcove, 1978; Ettinger et al., 1979; Carter, 1980; Rosen et al., 1981 . However, selection criteria in the MRC trial were generally less restrictive than in those studies. In particular only conventional X-ray examination and tomography were required to exclude lung metastases, so that some patients with lung metastases now identifiable by CT scanning may have been included. The main results are the comparisons made between the two drug and three drug regimens of adjuvant chemotherapy, showing no difference in lung metastases-free survival or in total survival.
However, toxicity was found to be substantially greater in patients receiving the three drug regimen. Cardiotoxicity was found in none of the 99 patients on the two drug regimen, compared with 13 of the 95 patients on the three drug regimen, with two deaths from cardiomyopathy. Mild myelosuppression occurred in 11 and 22 patients, and alopecia in 14 and 80 patients on the two and three drug regimens respectively.
Another aspect of management of patients with this disease is the treatment of lung metastases developing during follow-up. In this trial there were no survivors at 1 year among the 17 patients who had thoracotomy for more than one lung metastasis, but 9 out of 27 patients with a solitary metastasis were alive at periods of 21 to 41 months after thoracotomy. If other factors are favourable, thoracotomy may therefore be justified for patients with a single solitary metastasis.
There is a continued need for comparative trials of adjuvant chemotherapy in osteosarcoma. The fact that the survival rates in this study were lower than in the non-randomised studies in North America, referred to above, emphasises our lack of knowledge of the real magnitude of improvement afforded by use of adjuvant chemotherapy. Recently Rosen and Nirenberg (1982) have claimed remarkably good results from a protocol 'T-10', consisting of high-dose methotrexate given preoperatively, followed by cis-platinum and doxorubicin in addition to other drugs, in patients whose tumours have responded poorly. Good results with this complex regimen in clinical Stage I osteosarcoma, in a randomised comparison with no adjuvant chemotherapy, have now been reported by Eilber and Eckhardt (1985) . These findings provide further motivation for conducting randomised comparisons of adjuvant chemotherapy in this disease.
